Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
出版年份 2019 全文链接
标题
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
作者
关键词
-
出版物
Frontiers in Immunology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-06-07
DOI
10.3389/fimmu.2019.01296
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders
- (2019) Bosco Paes et al. EUROPEAN JOURNAL OF PEDIATRICS
- Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
- (2019) Mathilde Bas et al. JOURNAL OF IMMUNOLOGY
- Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies
- (2019) Michihiko Aoyama et al. mAbs
- Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
- (2019) Marina Caskey et al. NATURE MEDICINE
- Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors
- (2018) Mehabaw G. Derebe et al. IMMUNOLOGY LETTERS
- Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review
- (2018) Marcela Helena Gambim Fonseca et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection
- (2018) Rajeev Gautam et al. NATURE MEDICINE
- Combination therapy with anti-HIV-1 antibodies maintains viral suppression
- (2018) Pilar Mendoza et al. NATURE
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms
- (2018) Ryuta Wada et al. mAbs
- Immunotherapy for Head and Neck Cancer
- (2018) Felix Sim et al. Oral and Maxillofacial Surgery Clinics of North America
- Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
- (2017) Megan Lo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors
- (2017) Patricia A. Blundell et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'
- (2017) Paul J. Carter et al. NATURE REVIEWS DRUG DISCOVERY
- IgG Fc engineering to modulate antibody effector functions
- (2017) Xinhua Wang et al. Protein & Cell
- Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities
- (2017) Gillian Dekkers et al. Frontiers in Immunology
- Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity
- (2017) Benjamin Peschke et al. Frontiers in Immunology
- Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates
- (2017) Yijun Shen et al. PLoS One
- Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
- (2016) Xiang-Qing Yu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
- (2016) M. Pamela Griffin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity
- (2016) S. Giuntini et al. Clinical and Vaccine Immunology
- Immunoglobulin isotype knowledge and application to Fc engineering
- (2016) Randall J Brezski et al. CURRENT OPINION IN IMMUNOLOGY
- Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa
- (2016) Alysia A. Ahmed et al. JOURNAL OF STRUCTURAL BIOLOGY
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
- (2016) Tilman Schlothauer et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I
- (2016) Uwe Wessels et al. Bioanalysis
- The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
- (2015) Jonathan T. Sockolosky et al. ADVANCED DRUG DELIVERY REVIEWS
- Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
- (2015) Isaak Quast et al. JOURNAL OF CLINICAL INVESTIGATION
- Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins
- (2015) Liming Liu JOURNAL OF PHARMACEUTICAL SCIENCES
- Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
- (2015) Kevin O. Saunders et al. JOURNAL OF VIROLOGY
- Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding
- (2015) M Jack Borrok et al. mAbs
- Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a
- (2015) E. Arduin et al. MOLECULAR IMMUNOLOGY
- Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
- (2015) Daniel M. Czajkowsky et al. Scientific Reports
- Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells
- (2014) G. Romain et al. BLOOD
- Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
- (2014) Stylianos Bournazos et al. CELL
- IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions
- (2014) William Kelton et al. CHEMISTRY & BIOLOGY
- Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis
- (2014) Muthusamy Thiruppathi et al. JOURNAL OF AUTOIMMUNITY
- Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
- (2014) Vaheh Oganesyan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats
- (2014) T. Tawara et al. JOURNAL OF IMMUNOLOGY
- Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody
- (2014) Céline Monnet et al. mAbs
- The therapeutic monoclonal antibody market
- (2014) Dawn M Ecker et al. mAbs
- Crystal structure of deglycosylated human IgG4-Fc
- (2014) Anna M. Davies et al. MOLECULAR IMMUNOLOGY
- Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
- (2014) Sung-Youl Ko et al. NATURE
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
- (2013) Gabriel J. Robbie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis)
- (2013) Marzieh Niknami et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
- Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
- (2013) Futa Mimoto et al. mAbs
- Myeloid cells as effector cells for monoclonal antibody therapy of cancer
- (2013) Rens Braster et al. METHODS
- An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
- (2013) Omid Vafa et al. METHODS
- Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131
- (2013) F. Mimoto et al. PROTEIN ENGINEERING DESIGN & SELECTION
- H435-containing immunoglobulin G3 allotypes are transported efficiently across the human placenta: implications for alloantibody-mediated diseases of the newborn
- (2013) Helga Einarsdottir et al. TRANSFUSION
- Revisiting the Role of Glycosylation in the Structure of Human IgG Fc
- (2012) M. Jack Borrok et al. ACS Chemical Biology
- Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity
- (2012) Sang Taek Jung et al. ACS Chemical Biology
- Marketing approval of mogamulizumab
- (2012) Alain Beck et al. mAbs
- Mouse model recapitulating human Fc receptor structural and functional diversity
- (2012) P. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice
- (2012) Ajay Jain et al. ARTHRITIS RESEARCH & THERAPY
- C1q aggregate binding for the determination of anti-complementary activity of immunoglobulin products
- (2011) Thanae Georgakopoulos et al. BIOLOGICALS
- Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose
- (2011) C. Ferrara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
- (2011) Nigel M. Stapleton et al. Nature Communications
- Polymeric human Fc-fusion proteins with modified effector functions
- (2011) David N. A. Mekhaiel et al. Scientific Reports
- Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
- (2010) H. M. Horton et al. BLOOD
- IgG2m4, an engineered antibody isotype with reduced Fc function
- (2010) Zhiqiang An et al. mAbs
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
- (2010) Gregory L. Moore et al. mAbs
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
- Optimization of Fc-mediated effector functions of monoclonal antibodies
- (2009) William R Strohl CURRENT OPINION IN BIOTECHNOLOGY
- Identity of the elusive IgM Fc receptor (FcμR) in humans
- (2009) Hiromi Kubagawa et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Structure of the Murine Unglycosylated IgG1 Fc Fragment
- (2009) Matthias J. Feige et al. JOURNAL OF MOLECULAR BIOLOGY
- Structural characterization of a human Fc fragment engineered for lack of effector functions
- (2008) Vaheh Oganesyan et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model
- (2008) Asahi Ito et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- Terminal sugars of Fc glycans influence antibody effector functions of IgGs
- (2008) T Shantha Raju CURRENT OPINION IN IMMUNOLOGY
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
- Structural characterization of a mutated, ADCC-enhanced human Fc fragment
- (2008) Vaheh Oganesyan et al. MOLECULAR IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now